Betta Pharmaceuticals has filed a patent for a novel compound with cancer treatment activity. The patent also includes a method for preparing the compound and a pharmaceutical composition containing it. The compound is defined by a specific chemical formula and various substituents. GlobalData’s report on Betta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Betta Pharmaceuticals, cancer treatment biomarkers was a key innovation area identified from patents. Betta Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230203055A1) describes a compound of Formula (I) and its various forms, including tautomers, deuterated compounds, and pharmaceutically acceptable salts. The compound has a wide range of potential applications in the field of pharmaceuticals.
The compound is defined by several variables, including R1, R2, A, X1, X2, X3, X4, X5, X6, X7, R6, R7, R8, R9, R3, R4, R5, and R9a. These variables can independently take on various values, such as H, amino, halogen, cyano, hydroxyalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, or heterocyclyl. The compound can also have substituents, such as acryloyl or substituted acryloyl.
The patent claims also describe the compound's structure, including the presence of double bonds and single bonds. The compound can be represented by Formula (I-1) and falls within the scope of Formula (Ia) to Formula (Ie).
The patent claims further include the use of the compound in pharmaceutical compositions. These compositions contain a therapeutically effective amount of the compound and at least one pharmaceutically acceptable excipient. The compound can be used in the treatment and/or prevention of various diseases.
Additionally, the patent claims describe a method for preparing the compound of Formula (I). The method involves acylating a compound of Formula (IA) with a compound of X-R2 under basic conditions. X is a halogen, and the resulting compound can be in the form of Formula (I), its tautomers, deuterated compounds, or pharmaceutically acceptable salts.
Overall, this patent describes a compound of Formula (I) and its various forms, as well as its potential applications in pharmaceutical compositions and disease treatment/prevention. The patent also provides a method for preparing the compound.
To know more about GlobalData’s detailed insights on Betta Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
